NCT05495659

Brief Summary

Ureteral stents are the most commonly used postoperative implantable materials in urology. The indwelling ureteral stents often lead to the formation of encrustation, with an incidence of 10%, which will lead to complications such as obstruction, lower urinary tract symptom (LUTS), and difficulty in extubation. At present, there is no accurate and sensitive diagnostic criteria for ureteral stents encrustation. Previously, we developed the artificial intelligence-based ureteral stents encrustation identification software - GREE-AI Medical Software (GAIMS) with the collaboration of GREE ELECTRIC APPLIANCES,INCORPORATED.OF ZHUHAI(a city of Guangdong, China). In order to further evaluate the diagnostic sensitivity and accuracy of the software in practical clinical applications, and to verify its predictive ability for ureteral stents encrustation, the following single-center, prospective, double-blind, diagnostic cohort study is planned. This study will use the gold standard as a reference to evaluate the sensitivity and specificity of GAIMS for detecting ureteral stents encrustation. At the same time, it will be compared with non-enhanced contrast Computed Tomography examinations interpreted by clinical radiologists to evaluate the pros and cons of GAIMS in detecting ureteral stents encrustation.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
156

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2022

Completed
1 day until next milestone

Study Start

First participant enrolled

August 1, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 10, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2024

Completed
Last Updated

August 10, 2022

Status Verified

August 1, 2022

Enrollment Period

2 years

First QC Date

July 31, 2022

Last Update Submit

August 8, 2022

Conditions

Keywords

GREE-AI medical software, ureteral stent, encrustation

Outcome Measures

Primary Outcomes (1)

  • Number of participants with ureteral stent encrustation longer than 4mm measured by a ruler

    After indwelling the ureteral stent, ureteral stent encrustation will be formed, which affects the patency of the ureter or causes difficulty in extubation. Our observation outcome is to observe whether the ureteral stent encrustation formed.

    When the patient returns to the hospital to remove the ureteral stent, it may be 2 weeks to 1 year after the operation.

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

People aged 12-80 who are scheduled to undergo ureteral stent placement due to urinary calculi, obstruction, etc.; and the estimated time for ureteral stent placement is greater than 2 weeks but less than 1 year.

You may qualify if:

  • Patients who plan to undergo ureteral stent placement due to urinary calculi or urinary system obstruction;
  • Aged over 12 years old;
  • The estimated time of ureteral stent placement is more than 2 weeks but less than 1 year;
  • Voluntarily participate in this clinical study, abide by the requirements of this clinical study and sign the informed consent.

You may not qualify if:

  • Transplanted kidney, severe urinary system deformity, hydronephrosis caused by the compression of tumors of the urinary system and surrounding organs (such as cervical cancer);
  • There are serious diseases in heart, lung, liver and other major organs;
  • Pregnancy;
  • The subject cannot complete the study or comply with the requirements of the study (due to administrative reasons or other reasons).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

July 31, 2022

First Posted

August 10, 2022

Study Start

August 1, 2022

Primary Completion

August 1, 2024

Study Completion

November 30, 2024

Last Updated

August 10, 2022

Record last verified: 2022-08